FibroBiologics (FBLG) announced significant advancements in its Bone Marrow Organoid platform, which may offer new treatment options for hematopoietic cancers and age-related immune decline. The company’s proprietary Bone Marrow Organoids have demonstrated potential in multiple therapeutic applications: Pre-IND animal trials show that Transplantation of Bone Marrow Organoids into xenografted melanoma mouse model significantly reduced tumor size. The organoids enable efficient ex vivo gene editing, allowing for swift and targeted therapeutic interventions before transplantation. FibroBiologics’ Bone Marrow Organoids can be cryopreserved, offering a scalable and readily available treatment option for bone marrow transplantation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Faces Nasdaq Delisting Notice
- FibroBiologics Reports Increased Losses Amid R&D Expansion
- Positive Outlook on FibroBiologics, Inc. Due to Strategic Positioning and Clinical Progress in Fibroblast-Based Therapies
- FibroBiologics price target lowered to $10 from $12 at H.C. Wainwright
- FibroBiologics files patent application on generating multipotent cells